


What is claimed is:


1. A compound of Formula (I) or a salt, solvate, or physiologically functional derivative thereof:



(I)

wherein:


- R1 is hydrogen or C₁₋₆alkyl or as indicated by the dotted line is fused to the phenyl forming a 5 or 6 membered ring, optionally containing a double bond;
- n is 0, 1, 2, 3 or 4;
- R2 is aryl, optionally substituted by one or two groups selected from the group consisting of halogen, NH₂, hydroxy, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, aryl, aryloxy, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulfonyl and a group R₃R₄NSO₂ (wherein R₃ and R₄ are independently hydrogen or C₁₋₄alkyl), (CH₂)₀₋₃NHCOOC₁₋₄alkyl, and a 5- or 6-membered heteroaryl group;
- or n is 0 and R1 and R2, together with the nitrogen atom to which they are joined, form a 5- or 6-membered monocyclic heterocyclic ring or a 9- or 10-membered bicyclic heterocyclic ring wherein at least the ring which contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, and wherein the 5- or 6-membered monocyclic heterocyclic ring or the 9- or 10-membered bicyclic heterocyclic ring is optionally substituted by one or two groups selected from the group consisting of halogen, hydroxy, cyano, oxo, C₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, aryl, aryloxy and C₁₋₄alkoxycarbonyl; and
- X is indazolyl, pyrazolyl or a group



wherein


G is CH or N; and

Y₁ and Y₂ are independently hydrogen, halogen and a group NR₅R₆ (wherein R₅ and R₆ are independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, or




).

2. A compound as claimed in claim 1, wherein R1 is hydrogen.
3. A compound as claimed in claim 1 or claim 2, wherein n is 1 or 2.
4. A compound as claimed in any of claims 1-3, wherein R2 is aryl, optionally substituted by one or two groups selected from the group consisting of halogen and C₁₋₄alkoxy.
5. A compound as claimed in claim 1 or claim 2, wherein n is 0 and R1 and R2, together with the nitrogen atom to which they are joined, form a 6-membered monocyclic heterocyclic ring or a 10-membered bicyclic heterocyclic ring wherein at least the ring which each contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, wherein the 6-membered monocyclic heterocyclic ring or 10-membered bicyclic heterocyclic ring are both optionally substituted by one or two groups selected from oxo, C₁₋₄alkyl, phenyl and C₁₋₄alkoxycarbonyl.
6. A compound as claimed in any of claims 1-5, wherein X is indazolyl or pyrazolyl.
7. A compound as claimed in any of claims 1-5, wherein X is a group:



wherein Y₁ is hydrogen or halogen.

8. A compound as claimed in any of claims 1-5, wherein X is a group:



wherein one of Y₁ and Y₂ is hydrogen, and the other is hydrogen, halogen or a group NR₅R₆ wherein R₅ and R₆ are independently hydrogen, C₁₋₆alkyl or C₂₋₆alkenyl.

9. A compound as claimed in claim 1, which is:

N-benzyl-4-(4-pyridinyl)benzamide
N-(2-phenylethyl)-4-(4-pyridinyl)benzamide
N-(3-methoxybenzyl)-4-(4-pyridinyl)benzamide
N-(3-methoxybenzyl)-4-(1H-pyrazol-4-yl)benzamide
4-(2-chloro-4-pyridinyl)-N-(3-methoxybenzyl)benzamide
4-(2-amino-4-pyrimidinyl)-N-(3-methoxybenzyl)benzamide
N-(3-methoxybenzyl)-4-(4-pyrimidinyl)benzamide
4-[6-(allylamino)-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide
4-[6-amino-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide
4-(1H-indazol-5-yl)-N-(3-methoxybenzyl)benzamide
4-(2-amino-4-pyrimidinyl)-N-[[3-(methoxyloxy)phenyl]methyl]benzamide
4-(2-[[4-(methoxyloxy)phenyl]amino]-4-pyrimidinyl)-N-[[3-(methoxyloxy)phenyl]methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[(2-chlorophenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[(4-chlorophenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[(2-fluorophenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[[2-(methoxyloxy)phenyl]methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[(2-methylphenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[[4-(methoxyloxy)phenyl]methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-(2,3-dihydro-1H-inden-1-yl)benzamide
4-(2-amino-4-pyrimidinyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]benzamide
1,1-dimethylethyl({3-[[[4-(2-amino-4-pyrimidinyl)phenyl]carbonyl]amino)methyl]phenyl)methyl}carbamate
4-(2-amino-4-pyrimidinyl)-N-[(3-bromophenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[(3-chlorophenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[(3-fluorophenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-(phenylmethyl)benzamide
4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-[4-(methoxyloxy)phenyl]ethyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-phenylpropyl]benzamide
6-(2-amino-4-pyrimidinyl)-2-(phenylmethyl)-1(2H)-isoquinolinone
4-(2-amino-4-pyrimidinyl)-N-[(3-hydroxyphenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-[[3-[(difluoromethyl)oxy]phenyl]methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-(1-methyl-1-phenylethyl)benzamide
4-(2-amino-4-pyrimidinyl)-N-[(3,5-dichlorophenyl)methyl]benzamide
4-(2-amino-4-pyrimidinyl)-N-(4-biphenylmethyl)benzamide
4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylethyl]benzamide
1,1-dimethylethyl{3-[1-[[4-(2-amino-4-pyrimidinyl)phenyl]carbonyl]amino)ethyl]phenyl}carbamate
N-[(2-aminophenyl)methyl]-4-(2-amino-4-pyrimidinyl)benzamide
4-(2-amino-4-pyrimidinyl)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide

5-(2-amino-4-pyrimidinyl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
4-(2-amino-4-pyrimidinyl)-N-((1R)-1-[3-(methyloxy)phenyl]ethyl)benzamide
4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylpropyl]benzamide

or a salt, solvate or physiologically functional derivative thereof.

10. A compound as claimed in any of claims 1-9 for use in therapy.
11. A compound as claimed in any of claims 1-9 for use in the treatment of a disorder mediated by inappropriate ROCK-1 activity.
12. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate ROCK-1 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as defined in any of claims 1-9.
13. Use of a compound as defined in any of claims 1-9 in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate ROCK-1 activity.
14. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in any of claims 1-9 and one or more of pharmaceutically acceptable carriers, diluents and excipients.